UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000001602
Receipt No. R000001924
Scientific Title Qualitative and quantitative effects of aggressive lipid-lowering therapy on atherosclerosis: Evaluation of vulnerable plaque by 64-slice MD-CT
Date of disclosure of the study information 2008/12/26
Last modified on 2010/07/06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Qualitative and quantitative effects of aggressive lipid-lowering therapy on atherosclerosis: Evaluation of vulnerable plaque by 64-slice MD-CT
Acronym Qualitative and quantitative effects of aggressive lipid-lowering therapy on atherosclerosis: Evaluation of vulnerable plaque by 64-slice MD-CT
Scientific Title Qualitative and quantitative effects of aggressive lipid-lowering therapy on atherosclerosis: Evaluation of vulnerable plaque by 64-slice MD-CT
Scientific Title:Acronym Qualitative and quantitative effects of aggressive lipid-lowering therapy on atherosclerosis: Evaluation of vulnerable plaque by 64-slice MD-CT
Region
Japan

Condition
Condition Hypercholesterolemic patients with coronary plaque
Classification by specialty
Cardiology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The objective of this study is assess qualitative and quantitative effects of rosuvastatin, a new lipid-lowering drug, on coronary plaques in hypercholesterolemic patients with coronary plaque using 64-slice MD-CT.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes Change of CT value of plaque at Week 48
Key secondary outcomes 1)Rate of subjects with low density plaque (CT value <= 50) at Week 48
2)Percentage change of calcium score at Week 48
3)Change of rate of restenosis in blood vessel at Week 48
4)Change of remodeling index at Week 48
5)Percentage change of plaque volume at Week 48
6) Change of lipids (LDL-C, HDL-C, TG, LDL/HDL-C) at Week 48
7) Change of hs-CRP at Week 48
8) Relationship between changes of lipids (LDL-C, HDL-C, LDL-C/HDL-C) and CT value at Week 48

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Rosuvastatin will be administered for 48 weeks at a dose of 5 mg/day (2 rosuvastatin 2.5 mg tablet or 1 rosuvastatin 5 mg tablet).
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) Patients giving written consent after being provided with sufficient explanation about participation in this clinical trial
2) Patients aged 20 years or older, and no limitations on gender or hospitalization status
3) Patients with calcification score of 0 <
Key exclusion criteria 1) Patients who have received statins within one month before the study entry
2) Patient who doesn't obtain accurate CT value (ex: plaque contains thrombus.)
3) Patients who need to receive other lipid-lowering drugs apart from the test drug
4) Patients with the fasting TG level of more than 400 mg/dL
5) Patients with uncontrolled hypertension (SBP >= 160mmHg or DBP >= 100mmHg) or patients with diabetes (HbA1c >= 8.0%)
6) Patients with familial hypercholesterolemia
7) Patients with secondary hyperlipidemia due to thyroid dysfunction, Cushing's syndrome, nephrotic syndrome, systemic lupus erythematosus, etc.
8) Patients with atrial fibrillation
9) Patients on treatment with cyclosporine
10) Patients currently receiving hemodialysis
11) Patients with a history of serious adverse effects or allergy to HMG-CoA reductase inhibitors
12) Patients with malignant tumor or doubtful malignant tumor, or patients with history of malignant tumor
13) Patients with active liver disease or hepatic dysfunction (ALT, AST, ALP levels more than 2.5 times the upper limit of normal, or a total bilirubin of more than 3.0 mg/dL)
14) Patients with the serum creatinine of more than 1.8 mg/dL
15) Patients with the serum CK level at least 3 times the upper limit of normal
16) Patients who can not take -blockers
17) Patients with confirmed pregnancy, possible pregnancy
18) Patients who underwent coronary PCI
19) Patients who are ineligible for any other reason in the opinion of the investigator
Target sample size 50

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name katsuomi iwakura
Organization Sakurabashi Watanabe Hospital
Division name Department of Cardiovascular Medicine
Zip code
Address 2-4-32 Umeda, Kita-ku, Osaka
TEL 06-6341-8651
Email

Public contact
Name of contact person
1st name
Middle name
Last name Yasushi Koyama
Organization Sakurabashi Watanabe Hospital
Division name Department of Cardiovascular Medicine
Zip code
Address 2-4-32 Umeda, Kita-ku, Osaka
TEL 06-6341-8651
Homepage URL
Email medicine@watanabe-hsp.or.jp

Sponsor
Institute Sakurabashi Watanabe Hospital
Institute
Department

Funding Source
Organization JAPAN VASCULAR DISEASE RESEARCH FOUNDATION
Organization
Division
Category of Funding Organization Non profit foundation
Nationality of Funding Organization None

Other related organizations
Co-sponsor PL Hospital
Okamura Memorial Hospital
Tokushima Prefectural Central Hospital
Ichiriyama Imai Clinic
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2008 Year 12 Month 26 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2008 Year 05 Month 30 Day
Date of IRB
Anticipated trial start date
2008 Year 06 Month 01 Day
Last follow-up date
2011 Year 06 Month 01 Day
Date of closure to data entry
2011 Year 06 Month 01 Day
Date trial data considered complete
2011 Year 07 Month 01 Day
Date analysis concluded

Other
Other related information

Management information
Registered date
2008 Year 12 Month 26 Day
Last modified on
2010 Year 07 Month 06 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001924

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.